
Dr. Reddy’s delays semaglutide supplies due to quality issue
The story in brief
Dr. Reddy’s faced delays in semaglutide supplies due to quality issues, impacting availability. The company confirmed no safety risks and is investigating. Shares fell 5.24% to ₹1,278. The issue relates to semaglutide, the active ingredient in Wegovy and Ozempic. Dr. Reddy’s launched its generic injection Obeda and later a biosimilar tablet. It is developing the product in-house and committed to quality. The issue does not affect global regulatory filings.